Akari Therapeutics PLC ADR 2025年季度报告

Non-accelerated filer☒Smaller reporting company Emerging growth company☐If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new FINANCIAL INFORMATIONFinancial Statements (Unaudited) Condensed Consolidated Balance SheetsCondensed Consolidated Statements of Operations and Comprehensive LossCondensed Consolidated Statements of Shareholders' Equity (Deficit) Exhibits SIGNATURES GENERAL INFORMATIONUnless otherwise stated or the context requires otherwise, references in this Quarterly Report on Form 10-Q ( “Form 10-Q”) to“Akari,” the “company,” the “Company,” “we,” “us,” “our” or similar designations refer to Akari Therapeutics, Plc and its trade names or registered marks of their respective owners.Statements made in this Form 10-Q concerning the contents of any agreement, contract or other document are summaries of suchagreements, contracts or documents and are not complete description of all of their terms. If we filed any of these agreements, future drug candidates, and the plans and objectives of management are forward-looking statements. The words “believes,”“anticipates,” “estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “intend,” forward-looking statements, although not all forward-looking statements contain these identifying words. We cannot guarantee thatwe will actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not placeundue reliance on our forward-looking statements. These forward-looking statements involve known and unknown risks,uncertainties, and other factors, which may be beyond our control, and which may cause the actual results, performance, or $ CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization—Stock-based compensation1,015Gain on debt extinguishment(54)Change in fair value of warrant liabilities54Unrealized foreign currency exchange (gains) losses(27)Change in assets and liabilities:Prepaid expenses and other current assets84 CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from issuance of shares, net of issuance costs1,557Proceeds from employee vesting of restricted shares— Net cash provided by financing activities2,133Effect of exchange rates on cash—Net change in cash(17) Components of cash and restricted cash$2,582$Restricted cash60 SUPPLEMENTAL DISCLOSURES OF NONCASH ACTIVITIES:Financing costs in accrued expenses Financing costs, deposits received for share subscriptions in accounts payable$140$Issuance of share capital for settlement of related party debt$1,000$ Seller-financed purchases$499$SUPPLEMENTAL CASH FLOW DISCLOSURES:Cash paid for interest$7$The accompanying notes are an integral part of these condensed consolidated financial statements. merged with and into Peak Bio, with Peak Bio surviving the acquisition as a wholly owned subsidiary of Akari. Since the Company’s acquisition of Peak Bio in November 2024, Akari has focused substantially all of its efforts on the ADCplatform and pipeline of novel anti-cancer payloads with mechanisms of action that differ from existing therapies and theapplication of those payloads against clinically validated targets. Through its platform, the Company aims to establish a pipeline ofADC candidates that target and kill cancer cells and stimulate the immune system, all while overcoming the limitations inherent inexisting therapies. The Company’s activities since inception have consisted of performing research and development activities andraising capital. better-capitalized companies. preclinical and regulatory activities, and clinical trials. These activities may take several years and will require significant operatingand capital expenditures in the foreseeable future. There can be no assurance that these activities will be successful. If the Company Basis of presentationThe accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generallyaccepted accounting principles (“U.S. GAAP”) for interim financial information and the rules and regulations of the SEC andassumes that the Company will continue to operate as a going concern. Accordingly, they do not include all the information and balance sheet at December 31, 2024 has been derived from the audited consolidated financial statements at that date. Theseunaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidatedfinancial statements as of December 31, 2024 and notes thereto included in its Form 10-K, as filed with the SEC on April 15, 2025. in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actualresults may differ from those estimates or assumptions. Liquidity and Financial ConditionThe